About this Journal Submit a Manuscript Table of Contents
The Scientific World Journal
Volume 2012 (2012), Article ID 925925, 7 pages
http://dx.doi.org/10.1100/2012/925925
Research Article

Synthesis and Anti-Inflammatory Activity of New Alkyl-Substituted Phthalimide 1H-1,2,3-Triazole Derivatives

1Laboratório de Química e Metabolismo de Lipídeos e Lipoproteínas, Departamento de Bioquímica, Universidade Federal de Pernambuco (UFPE), Avenida Prof. Moraes Rego s/n, 50670-420 Recife, PE, Brazil
2Laboratório de Síntese de Compostos Bioativos (LSCB), Departamento de Ciências Moleculares, Universidade Federal Rural de Pernambuco (UFRPE), Rua Dom Manoel de Medeiros s/n, Dois Irmãos, 52171-900 Recife, PE, Brazil

Received 2 October 2012; Accepted 23 October 2012

Academic Editors: A. Brandi, J. H. Li, A. Marra, and G. B. Shul'pin

Copyright © 2012 Shalom Pôrto de Oliveira Assis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Four new 1,2,3-triazole phthalimide derivatives with a potent anti-inflammatory activity have been synthesized in the good yields by the 1,3-dipolar cycloaddition reaction from N-(azido-alkyl)phthalimides and terminal alkynes. The anti-inflammatory activity was determined by injecting carrageenan through the plantar tissue of the right hind paw of Swiss white mice to produce inflammation. All the compounds 3a–c and 5a–c exhibited an important anti-inflammatory activity; the best activity was found for the compounds 3b and 5c, which showed to be able to decrease by 69% and 56.2% carrageenan-induced edema in mice. These compounds may also offer a future promise as a new anti-inflammatory agent.

1. Introduction

Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for reducing pain and swellings associated with inflammation and represent an area in continuous and evergrowing development. Phthalimide derivatives are an interesting class of compounds because they possess important biological activities [1], such as anti-inflammatory [2] and hypolipidemic [3, 4] ones. Glycoconjugates play an important role in many biological processes, including cellular recognition, particularly in cases of inflammation, tumor metastasis, and immune response in bacterial and viral infections [5].

The literature describes a series of N-phthalimidomethyl 2,3-dideoxy- and 2,3-unsaturated sugar derivatives that showed a potent anti-inflammatory activity, by exhibiting reduction of the edema induced by carrageenan [2]. The anti-inflammatory activity has also been recently related to 1,2,3-triazole derivatives [6]. The 1,2,3-triazole is a five-membered ring structure containing three nitrogen atoms and is a ring bioisosterism case of the 1,2,4-triazole. Triazoles and derivatives display a diversity of biological activities [7], such as anti-inflammatory [6, 8], hypolipidemic [4], antimicrobial [9], anticonvulsant, [10] and anti-nociceptive [11] ones. Most of these compounds and their related activity are associated with an anti-inflammatory profile [8, 9].

1,2,3-Triazole represents a class of compounds that has awakened an interest in our research group by the synthesis of new heterocyclic derivatives and their biological evaluation [1214]. In this work the synthesis and anti-inflammatory activity of six compounds based on 1,2,3-triazoles it were performed. One group of compounds was 1,2,3-triazoles linked to unsaturated carbohydrate and phthalimides (CTP), and another one was 1,2,3-triazoles linked to phthalimides (PTP), as shown in Figure 1. These compounds were obtained through the reaction between N-(azido-alkyl) phthalimides and terminal alkynes employing Cu-AAC (Cu-Catalyzed Azide Alkyne Cycloadditon) reaction [15].

fig1
Figure 1: Molecules based on Carbohydrate-Triazole-Phthalimides (CTP) and Phthalimide-Triazole-Phthalimides (PTP).

2. Materials and Methods

2.1. Chemistry

All reactions were monitored by TLC analysis containing GF254 and revealed in vanillin. Melting points were determined in an open capillary tube and performed on a PFM II BioSan apparatus. Elemental analyses were carried out on an EA 1110 CHNS-O analyzer from Carlo Erba Instruments. The infrared spectra were recorded on an IFS66 Bruker spectrophotometer using KBr discs. 1H and 13C NMR were obtained on Varian Unity Plus-300 and Varian UNMRS 400 MHz spectrometer using CDCl3 or DMSO-d6 as a solvent. The polarimeter used was the Krüss, of 10 cm path length and concentration of the solution in g/100 mL. The purity of the compounds was attested on an HPLC-DAD Shimadzu Prominence Model.

2.1.1. Synthesis of the Compound 1

The compound 1 was prepared according to a reported procedure [16]. The 1H and 13C NMR data were according to the literature [17]. Yield: 82%. Mp 48°C. (c 0.5, CH2Cl2).

2.1.2. Synthesis of the Compounds 2ac

The compounds 2a–c were prepared as previously reported, and the 1H and 13C NMR data were according to the literature [12].

N-2-(azidoethyl)phthalimide 2a
Yield: 75%. Solid. Mp 60-61°C.

N-3-(azidopropyl)phthalimide 2b
Yield: 76%. Solid. Mp 40°C.

N-4-(azidobutyl)phthalimide 2c
Yield: 70%. Solid. Mp 45–48°C.

2.1.3. Synthesis of the Compounds 3ac

The compound 1 (200 mg, 0.69 mmol) was transferred into 50 mL flask, and it was added to 10 mL of dichloromethane. Then, a solution containing 20 mol% copper iodide (0.0268 g, according to alkyne-compound), azide-phthalimides 2a–c (1.2 equiv), and triethylamine (0.006 g~1 drop) was added. The mixture was stirred overnight (12 h) at r.t. (28°C) under argon atmosphere. A thin layer chromatography (TLC) was used to check the end of the reaction, using hexane : EtOAc (7 : 3) as the developing solvent system. The purification was performed by column chromatography on Merck silica gel 60 (70–230 mesh), using a system hexane : EtOAc (5 : 5). After the solvent evaporation, the product was crystallized in ethyl acetate.

4-(4,6-di-O-acetyl-2,3-dideoxy-α-D-erythro-hex-2-enopyranoside)-O-methyl-1-(2-phthalimidoethyl)-1,2,3-triazole (3a)
Yield: 90%. Solid. Mp 103–106°C. (hexane : EtOAc, 3 : 7). (c 1, CH2Cl2); IR (KBr, cm−1): 3400, 3100, 2950, 1716, 1428, 1395, 1237, 1042, 718. 1H NMR (300 MHz, DMSO-d6): δ 2.02 (s, 3H, CH3CO), 2.06 (s, 3H, CH3CO), 3.94–4.03 (m, 3H, NCH2 and H-5), 4.11–4.16 (m, 2H, H-6 and H-6′), 4.56–4.70 (m, 4H, OCH2 and NCH2Phth), 5.09 (bs, 1H, H-1), 5.20 (dd, 1H, and 1.5 Hz, H-4), 5.83–5.85 (m, 2H, H-2 and H-3), 7.84 (m, 4H, phthalimide), 8.18 (s, 1H, Htriazole). 13C NMR (75.5 MHz, CDCl3): δ 20.8, 20.9, 37.6, 47.9, 61.2, 62.0, 65.2, 66.9, 93.4, 123.6, 127.5, 129.4, 131.6, 134.3, 167.6, 170.3, 170.8. Anal. Calc. for C23H24N4O8: C, 57.02; H, 4.99; N, 11.56. Found: C, 57.29; H, 5.36; N, 11.42.

4-(4,6-di-O-acetyl-2,3-dideoxy-α-D-erythro-hex-2-enopyranoside)-O-methyl-1-(3-phthalimidopropyl)-1,2,3-triazole (3b)
Yield: 81%. Solid. Mp 125–127°C. (hexane : EtOAc, 3 : 7). (c 1, CH2Cl2); IR (KBr, cm−1): 3468, 2925, 2854, 1770, 1710, 1491, 1399, 1231, 1037, 722. 1H NMR (300 MHz, DMSO-d6): δ 2.03 (s, 3H, CH3CO), 2.05 (s, 3H, CH3CO), 2.18 (q, 2H, NCH2), 3.61 (t, 2H,  Hz, NCH2), 3.98 (ddd, 1H, , 5.1 and 3.0 Hz, H-5), 4.12–4.15 (m, 2H, H-6 and H-6′), 4.42 (t, 2H,  Hz), 4.59 (d, 1H,  Hz, OCHa), 4.72 (d, 1H,  Hz, OCHb), 5.17 (s, 1H, H-1), 5.20 (d, 1H,  Hz, H-4), 5.86 (bs, 2H, H-2 and H-3), 7.82–7.87 (m, 4H, phthalimides), 8.12 (s, 1H, Htriazole). 13C NMR (75.5 MHz, CDCl3): δ 20.8, 20.9, 29.4, 34.9, 47.2, 60.5, 62.8, 65.2, 67.0, 93.8, 122.0, 123.4, 127.5, 128.8, 129.5, 131.7, 134.3, 143.3, 168.3, 170.3, 170.9. Anal. Calc. for C24H26N4O8: C, 57.83; H, 5.26; N, 11.24. Found: C, 57.88; H, 5.46; N, 11.14.

4-(4,6-di-O-acetyl-2,3-dideoxy-α-D-erythro-hex-2-enopyranoside)-O-methyl-1-(4-phthalimidobutyl)-1,2,3-triazole (3c)
Yield: 68%. Solid. Mp 103–106°C. 0.40 (hexane : EtOAc, 3 : 7). (c 1, CH2Cl2); IR (KBr, cm−1): 3464, 3141, 2935, 1769, 1711, 1437, 1398, 1370, 1230, 1038, 721. 1H NMR (400 MHz, DMSO-d6): δ 1.54–1.60 (q, 2H, CH2), 1.82–1.85 (q, 2H, CH2), 2.03 (s, 3H, CH3CO), 2.05 (s, 3H, CH3CO), 3.60 (t, 2H,  Hz, NCH2), 3.98 (ddd, 1H, , 5.2 and 3.2 Hz, H-5), 4.09–4.17 (m, 2H, H-6 and H-6′), 4.37 (t, 2H,  Hz), 4.60 (d, 1H,  Hz, OCHa), 4.72 (d, 1H,  Hz, OCHb), 5.17 (s, 1H, H-1), 5.20 (d, 1H,  Hz, H-4), 5.86 (bs, 2H, H-2 and H-3), 7.82–7.87 (m, 4H, phthalimides), 8.10 (s, 1H, Htriazole). 13C NMR (75.5 MHz, CDCl3): δ 20.8, 20.9, 25.5, 27.4, 29.6, 36.7, 49.4, 61.4, 62.7, 65.1, 66.9, 93.7, 122.7, 123.2, 127.4, 129.4, 131.8, 134.0, 144.0, 168.3, 170.2, 170.8. Anal. Calc. for C25H28N4O8: C, 58.59; H, 5.51; N, 10.93. Found: C, 58.47; H, 5.30; N, 10.56.

2.1.4. Synthesis of the Compounds 5a–c

The N-(azido-alkyl)phthalimide 2a–c was transferred into 50 mL flask and it was added to 10 mL of dichloromethane. Then, a solution of 20 mol% copper iodide (according to alkyne-compound), 1.5 equiv. N-propargyl phthalimide 4, and triethylamine (20 mol%) was added. The mixture was stirred for 12 h at room temperature (28°C) under argon atmosphere. The purification was performed by column chromatography on Merck silica gel 60 (70–230 mesh). After the solvent evaporation, the product was crystallized in dichloromethane-hexane.

4-(N-Phthalimidomethyl)-1-(2-phthalimidoethyl)-1,2,3-triazole (5a)
Yield: 77%. Solid. Mp 226–230°C. 0.14 (hexane : EtOAc, 1 : 1). IR (KBr, cm−1): 3582, 3459, 3144, 3094, 2951, 1771, 1703, 1466, 1428, 1398, 1322, 1224, 1101, 936, 718, 531. 1H NMR (400 MHz, CDCl3): δ 4.13 (t, 2H,  Hz, NCH2), 4.64 (t, 2H,  Hz, NCH2), 4.97 (s, 2H, CH2), 7.68–7.73 (m, 5H, phthalimide and Htriazole), 7.78 (m, 2H, phthalimide), 7.85 (m, 2H, phthalimide). 13C NMR (100 MHz, CDCl3): δ 33.0, 37.6, 47.9, 123.4, 123.6, 131.7, 132.1, 134.0, 134.2, 167.6. Anal. Calc. for C21H15N5O4 (0.9·H2O): C, 60.40; H, 4.05; N, 16.77. Found: C, 60.70; H, 4.35; N, 16.49.

4-(N-Phthalimidomethyl)-1-(3-phthalimidopropyl)-1,2,3-triazole (5b)
Yield: 62%. Solid. Mp 150–152°C; 0.44 (CH2Cl2 : EtOAc, 9 : 1). The NMR 1H and 13C data is in accordance with the literature [12].

4-(N-Phthalimidomethyl)-1-(4-phthalimidobutyl)-1,2,3-triazole (5c)
The purification started with 20% EtOAc in hexane to 100% ethyl acetate. The product was crystallized in dichloromethane and hexane. Yield: 88%. Solid. Mp 151–153°C; Lit. 150–151°C. 0.34 (CH2Cl2 : EtOAc, 9 : 1). The spectroscopic data is in agreement with the reported data [12].

2.2. Pharmacology
2.2.1. Animals

Three-month-old Swiss white mice, 25–30 g body weight, were maintained with water and food (Labina, Agribands Brazil Ltd.) ad libitum. Groups of 10 animals were separate for each experiment. All experiments reported here are in accordance with the Animal Care and Use Committee at the Federal University of Pernambuco and guidelines for Care and Use of Laboratory Animals (of. number 098/2002).

2.2.2. Acute Anti-Inflammatory Activity

The drugs used for comparison purposes were 3a–c, 5a–c, ibuprofen, and ASA. All compounds were suspended in 1% carboxymethylcellulose (CMC) and single dose of 250 mg/Kg was administered intraperitoneally, in the morning [18]. Other animal group received 1% CMC. Two positive and one negative anti-inflammatory control tests were done in three animal groups by intraperitoneal administration of 250 mg/Kg of acetylsalicylic acid (ASA), a standard dose for pharmacological comparative tests, 250 mg/Kg of ibuprofen (Laboratory Teuto Brazilian Ltd., Brazil), and 0.9% of aqueous saline solution, respectively. The anti-inflammatory activity was determined by Levy’s method [19]. Carrageenan (Sigma, St. Louis, USA), 0.1 mL of a 1% solution in 0.9% NaCl, was injected through the plantar tissue of the right hind paw of each mouse to produce inflammation. After four hours, the animals were sacrificed under anesthesia and their paws were cut and weighed. The results were analyzed according to the percentage of inflammation reduction as described earlier [19].

2.2.3. Effective Dose for Anti-Inflammatory Activity

Compounds 3b and 5c, ASA, and ibuprofen (obtained from Bristol-Myers Squibb, Brazil) were dissolved individually in 1% CMC and administrated as described above at doses of 50, 100, 150, 200, 250, and 350 mg/Kg.

2.2.4. Calculation of Octanol-Water Partition Coefficient [20]

The structures of compounds 3a–c and 5a–c were analyzed in ACD/Labs that contains a database available for this procedure. The values of octanol-water partition coefficient ( ) for these compounds were predicted using Advanced Chemistry Development Inc. (ACD/Labs, algorithm version: v5.0.0.184).

2.2.5. Statistics

All results are expressed as mean ± SEM for experiments. Statistical evaluation was undertaken by analysis of variance (ANOVA) followed by Turkey test for multiple comparisons. was used as the criterion of statistical significance.

3. Results and Discussion

3.1. Chemistry

The synthetic strategy to obtain the compounds 3a–c consists of two convergent steps. First, the alkyne carbohydrate 1 was prepared in 82% of yield according to Ferrier’s protocol [16]. In parallel, the synthesis of N-(azido-alkyl)phthalimides 2a–c was achieved from the corresponding N-(bromoalkyl)phthalimide in good yields (70%–75%). Finally, the glycoconjugate 1,2,3-triazoles 3a–c were initially prepared using the protocol described in a previous work [12] to afford the compound 3a in moderate yield (48%). Thus, when 1 drop of triethylamine was added the desired compounds were obtained in good yield (90%). Under this optimized conditions the compounds 3a–c were synthesized in good yields of 68%–90% after column chromatography on silica gel (Scheme 1).

925925.sch.001
Scheme 1: Synthesis of compounds 3a–c.

The N-propargyl phthalimide 4 was prepared from potassium phthalimide and propargyl bromide after being stirred at room temperature for 24 h. The reaction between alkyne 4 and N-(azido-alkyl)-phthalimides 2a–c was carried out at the same conditions described above. This facile protocol provided the bis-phthalimides 1,2,3-triazole 5a–c in good yields of 62%–88%, as shown in Scheme 2.

925925.sch.002
Scheme 2: Synthesis of compounds 5a–c.
3.2. Pharmacology

All the compounds exhibited anti-inflammatory activity when compared with ASA as well as ibuprofen. The compounds 3a, 3b, and 3c reduced carrageenan-induced edema in Swiss white mice by 33.7%, 69%, and 44%, respectively. This result is significant ( ) when compared with the control group treated with the saline solution (Table 1).

tab1
Table 1: Acute anti-inflammatory activity of 1,2,3-triazole phthalimides 3a–c and 5a–c after carrageenin-induced edema at dose 250 mg·kg−1.

The compounds 5a, 5b, and 5c were able to reduce the edema by 17%, 25%, and 56.2%, respectively, as shown in Table 1. Therefore, substances 3b and 5c showed the best anti-inflammatory activity in terms of edema inhibition.

The 3b and 5c compounds, which showed the greatest anti-inflammatory effect, were selected for the experiment of determining the effective dose. The study of effective dose has shown that closely at concentration of 225 mg/Kg the compounds 3b and 5c have 50% of anti-inflammatory activity (Figure 2). The results of anti-inflammatory dose-response curves for the compounds 3b and 5c showed similar results to the ASA at all concentrations tested. On the other hand, the anti-inflammatory effect of compounds 3b and 5c was similar to ibuprofen only when administered at high dose (350 mg/Kg), as shown in Figure 2.

925925.fig.002
Figure 2: Anti-inflammatory dose-response curves for compounds 3b, 5c, ASA, and ibuprofen using carrageenan to produce inflammation in the paw of mice.

According to Table 1 the acute anti-inflammatory activity of considering the compounds 3a–c containing phthalimide linked to carbohydrate (CTP) the best anti-inflammatory activity was observed for the compound 3b that contains three methylene groups. However, for compounds 5a–c that have two moieties of phthalimide connected to a triazole ring (PTP), when increasing the size of aliphatic chain, the anti-inflammatory activity is also increased from 17% ( ) to 56.2% ( ) (Table 1 and Figure 3).

925925.fig.003
Figure 3: Analysis of anti-inflammatory activity (%) versus variation of size aliphatic chain in the compounds 3a–c (CTP) and 5a–c (PTP).

Hydrophobic interactions play a key role in the folding and maintenance of the three-dimensional structure of proteins, as well as in the binding of ligands (e.g., drugs) to protein targets [21]. Protein-ligand binding is partially driven by lipophilic interaction, and the for a class of ligand compounds will depend on the nature of protein. In fact, it is known in the literature that chain branching or homologation can cause the molecule to bind more or less well to the receptors responsible for specific biological activity [22].

In order to evaluate the chain effect on the anti-inflammatory activity we have calculated the partition coefficient ( ) using the ADC/Labs PhysChem Predictor. The values are important data to be considered for drug design and their pharmacokinetics properties; they indicate the lipophilic tendency or the ability to penetrate lipid barriers (lipophilicity) [23].

The chain effect for the biological activity in both classes of the compounds 3 and 5 is shown in Table 2, and the ranged from 1.53 to 2.04 and from 2.37 to 2.89, respectively.

tab2
Table 2: Structure activity and values calculated.

The compounds 3a–c have a portion carbohydrate, and for this class we can note that a peak anti-inflammatory activity occurred with the 3-phthalimide propyl-1,2,3-triazole 3b (Figure 3). On the other hand, the class of compounds 5a–c is more lipophilic and showed to be sensitive to anti-inflammatory activity when the methylene groups were introduced.

In recent works, a new series of 1-[2-(1H-tetrazol-5-yl)ethyl]-1H-benzo[d] triazoles have shown anti-inflammatory activity (11–47%) against carrageenan-induced paw edema, whereas the standard drug diclofenac sodium showed 61% [24]. Other novel series of azoles, such as pyrazole, were obtained by reacting chalcones and hydrazine hydrate, and they exhibited low inhibition of paw edema ranging 1.08–31.05%, and these results corresponded to a percentage of the indomethacin inhibition [25]. However, in the present work, the compounds 3b and 5c exhibited better anti-inflammatory activity (Figure 2) than that reported by Khalil [25], when considering the anti-inflammatory effect of 3b and 5c observed with 50 mg/Kg (lower dose) in relation to the same concentration of ibuprofen or ASA instead of that of the saline.

Recently, a series of new 1,2,4-triazoles obtained by reacting acyl 1,2,4-triazoles with various secondary amines, exhibited appreciable inhibition [8]; when, administered at a dose of 100 mg/Kg, the percentage inhibition reached 55.6%, the comparison was performed with the reference drug indomethacin (62.5% at 100 mg/Kg). These results are similar to the compounds 3b and 5c, which were administered by us at a dose of 250 mg/Kg.

There are scientific evidences that the bis-heterocyclic compounds encompassing 2-mercapto benzothiazole and 1,2,3-triazole showed significant binding potential towards COX enzyme thus lowering the paw edema induced by carrageenan [6]. The class of monoacylated 5-amino-1,2,4-triazole derivatives exhibited potent anti-inflammatory activity (at 5 mg/kg, oral dose level) in carrageenan-induced rat paw edema test [26]. These results also contributed to show that many structure containing the heterocyclic triazole possessed high anti-inflammatory activity.

New 1H-(1,2,3-triazole)phthalimide derivatives are interesting drugs due to their potential anti-inflammatory activity, thus deserving further studies in order to understand the mechanism of action. In conclusion, the results suggest that these compounds may also offer a future promise as a new anti-inflammatory agent.

Acknowledgments

The authors are grateful to Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco (FACEPE), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), and Brazilian agencies for financial support. They authors are indebted to the Analytical Centers DQF-UFPE and CENAPESQ-UFRPE.

References

  1. R. A. W. Neves Filho, M. A. T. Palm-Forster, and R. N. De Oliveira, “Imidazole-promoted Synthesis of N-substituted phthalimides from N,N’-disubstituted ureas in solventless conditions,” Synthesis Communication. In press. Online first at http://www.tandfonline.com/doi/abs/10.1080/00397911.2011.651677. View at Publisher · View at Google Scholar
  2. X. B. Meng, D. Han, S. N. Zhang, W. Guo, J. R. Cui, and Z. J. Li, “Synthesis and anti-inflammatory activity of N-phthalimidomethyl 2,3-dideoxy- and 2,3-unsaturated glycosides,” Carbohydrate Research, vol. 342, no. 9, pp. 1169–1174, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. I. H. Hall, P. J. Voorstad, J. M. Chapman, and G. H. Cocolas, “Antihyperlipidemic activity of phthalimide analogues in rodents,” Journal of Pharmaceutical Sciences, vol. 72, no. 8, pp. 845–851, 1983. View at Scopus
  4. V. L. M. Sena, R. M. Srivastava, R. O. Silva, and V. L. M. Lima, “Synthesis and hypolipidemic activity of N-substituted phthalimides. Part V,” Farmaco, vol. 58, no. 12, pp. 1283–1288, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Hölemann and P. H. Seeberger, “Carbohydrate diversity: synthesis of glycoconjugates and complex carbohydrates,” Current Opinion in Biotechnology, vol. 15, no. 6, pp. 615–622, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Shafi, M. M. Alam, N. Mulakayala et al., “Synthesis of novel 2-mercapto benzothiazole and 1, 2, 3-triazole based bis-heterocycles: their anti-inflammatory and anti-noceptive activites,” European Journal Medicinal Chemistry, vol. 49, no. 31, pp. 324–333, 2012.
  7. S. G. Agalave, S. R. Maujan, and V. S. Pore, “Click chemistry: 1, 2, 3-triazole as pharmacophores,” Chemistry Asian Journal, vol. 6, no. 10, pp. 2696–2718, 2011.
  8. N. Upmanyu, J. K. Gupta, K. Shah, and P. Mishra, “Synthesis of new 1,2,4-triazoles as anti-inflammatory and anti-nociceptive agents,” Pharmaceutical Chemistry Journal, vol. 45, no. 7, pp. 433–439, 2011.
  9. P. Karegoudar, D. J. Prasad, M. Ashok, M. Mahalinga, B. Poojary, and B. S. Holla, “Synthesis, antimicrobial and anti-inflammatory activities of some 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles and 1,2,4-triazolo[3,4-b][1,3,4]thiadiazines bearing trichlorophenyl moiety,” European Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 808–815, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. L. P. Guan, Q. H. Jin, G. R. Tian, K. Y. Chai, and Z. S. Quan, “Synthesis of some quinoline-2(1H)-one and 1, 2, 4 - triazolo [4, 3 -a] quinoline derivatives as potent anticonvulsants,” Journal of Pharmacy & Pharmaceutical Sciences, vol. 10, no. 3, pp. 254–262, 2007. View at Scopus
  11. A. Rajasekaran and K. A. Rajagopal, “Synthesis of some novel triazole derivatives as anti-nociceptive and anti-inflammatory agents,” Acta Pharmaceutica, vol. 59, no. 3, pp. 355–364, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. F. C. G. Barbosa and R. N. De Oliveira, “Synthesis of a new class of triazole-linked benzoheterocycles via 1,3-dipolar cycloaddition,” Journal of the Brazilian Chemical Society, vol. 22, no. 3, pp. 592–597, 2011. View at Scopus
  13. W. S. Nascimento, C. A. Camara, and R. N. De Oliveira, “Synthesis of 2-(1H-1, 2, 3-triazole-1-yl)-1, 4-naphthoquinones from 2-azide-1, 4-naphthoquinone and terminal alkynes,” Synthesis, vol. 20, no. 20, pp. 3220–3224, 2011.
  14. E. N. Da Silva Jr., I. M. M. De Melo, E. B. T. Diogo, et al., “On the search for potential anti-trypanosoma cruzi drugs: synthesis and biological evaluation of 2-hydroxy-3-methylamino and 1, 2, 3-triazolic naphthoquinoidal compounds obtained by click chemistry reaction,” European Journal Medicinal Chemistry, vol. 52, pp. 304–312, 2012.
  15. V. V. Rostovtsev, L. G. Green, V. V. Fokin, and K. B. Sharpless, “A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective ‘Ligation’ of azides and terminal alkines,” Angewandte Chemie International Edition, vol. 41, pp. 2596–2599, 2002.
  16. K. Toshima, T. Ishizuka, G. Malsuo, and M. Nakata, “Practical glycosidation method of glycals using montmorillonite K-10 as an environmentally acceptable and inexpensive industrial catalyst,” Synlett, vol. 4, no. 11, pp. 306–308, 1995.
  17. K. De, J. Legros, B. Crousse, and D. Bonnet-Delpon, “Synthesis of 2,3-unsaturated glycosides via metal-free Ferrier reaction,” Tetrahedron, vol. 64, no. 46, pp. 10497–10500, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. E. P. D. S. Falcão, S. J. De Melo, R. M. Srivastava, M. T. J. D. A. Catanho, and S. C. Do Nascimento, “Synthesis and antiinflammatory activity of 4-amino-2-aryl-5-cyano-6-{3- and 4-(N-phthalimidophenyl)} pyrimidines,” European Journal of Medicinal Chemistry, vol. 41, no. 2, pp. 276–282, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Levy, “Carrageenan paw edema in the mouse,” Life Sciences, vol. 8, no. 11, pp. 601–606, 1969. View at Scopus
  20. A. A. Petrauskas and E. A. Kolovanov, “ACD/Log P method description,” Perspectives in Drug Discovery and Design, vol. 19, no. 1, pp. 99–116, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. R. G. Efremov, A. O. Chugunov, T. V. Pyrkov, J. P. Priestle, A. S. Arseniev, and E. Jacoby, “Molecular lipophilicity in protein modeling and drug design,” Current Medicinal Chemistry, vol. 14, no. 4, pp. 393–415, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. R. B. Silverman, The Organic Chemistry of Drug Design and Drug Action, Elsevier/Academic Press, Burlington, Mass, USA, 2004.
  23. T. Nogrady and D. F. Weaver, Medicinal Chemistry: A Molecular and Biochemical Approach, Oxford University Press, New York, NY, USA, 3rd edition, 2005.
  24. A. Rajasekaran and K. A. Rajagopal, “Synthesis of some novel triazole derivatives as anti-nociceptive and anti-inflammatory agents,” Acta Pharmaceutica, vol. 59, no. 3, pp. 355–364, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. O. M. Khalil, “Synthesis and anti-inflammatory of 1-acetyl/propanoyl-5-aryl-3-(4-morpholinophenyl)-4, 5-dihydro-1H-pyrazole derivatives,” Medicinal Chemistry Research, vol. 21, no. 10, pp. 3240–3245, 2012.
  26. A. M. Abdel-Megeed, H. M. Abdel-Rahman, G. E. S. Alkaramany, and M. A. El-Gendy, “Design, synthesis and molecular modeling study of acylated 1,2,4-triazole-3-acetates with potential anti-inflammatory activity,” European Journal of Medicinal Chemistry, vol. 44, no. 1, pp. 117–123, 2009. View at Publisher · View at Google Scholar · View at Scopus